Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
- Conditions
- Any Solid TumorGliomaCholangiocarcinomaChondrosarcoma
- Interventions
- Registration Number
- NCT04521686
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.
- Detailed Description
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with IDH1 R132-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or IDH2 R140 or R172 mutant cholangiocarcinoma.
This study includes 2 parts: Phase 1 dose escalation and Phase 1 dose expansion. The Phase 1 dose escalation monotherapy cohort will enroll any eligible patient with IDH1 R132-mutant advanced solid tumor or IDH1 or IDH2 mutant cholangiocarcinoma. The Phase 1 dose expansion will include 5 cohorts to further evaluate safety and clinical activity. Three cohorts will be administered LY3410738 monotherapy. The fourth cohort will administer LY3410738 at or below the monotherapy RP2D in combination with gemcitabine and cisplatin. The fifth cohort (US only) will administer LY3410738 at or below the monotherapy RP2D in combination with durvalumab.
IDH1 R132, IDH2 R140, or IDH2 R172 mutations will be identified through genomic testing utilizing material collected prior to patient consent. Molecular assays utilized for enrollment are required to be performed in CLIA, ISO/IEC, CAP, or other similarly certified laboratory. Enrollment of patients with cholangiocarcinoma, chondrosarcoma or glioma may be made based on molecular tests performed in either tumor or blood. Enrollment of patients with other tumor types is limited to testing performed in tumor tissue.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 200
-
Evidence of IDH1 R132 mutation (any solid tumor) or circulating tumor DNA IDH2 R140 or IDH2 R172 mutation (cholangiocarcinoma only) as determined by molecular testing performed at a CLIA, ISO/IEC, CAP, or other similarly certified laboratory. For cholangiocarcinoma, chondrosarcoma, and glioma, molecular testing can be performed on tumor tissue or circulating tumor DNA. For all other solid tumor types, molecular testing must be performed on tumor tissue.
-
Availability of an archived tumor tissue sample. Patients without an available archival tumor tissue sample must be discussed with the sponsor's Medical Monitor prior to enrollment.
-
Eastern Cooperative Oncology Group (ECOG) 0-1.
-
At least 18 years of age.
-
Adequate organ function.
-
Ability to swallow capsules or tablets.
-
Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation.
-
For cholangiocarcinoma patients, must have adequate biliary drainage (per investigator's discretion), with no evidence of ongoing infection.
-
Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following the last dose of study treatment. Patients enrolled to Dose Expansion Cohort 4 shall also follow cisplatin/gemcitabine contraception duration requirements as determined by labels and/or local guidelines. Patients enrolled in dose expansion Cohort 5 should follow durvalumab contraception duration requirements as determined by the durvalumab label and/or local guidelines.
Monotherapy Dose Escalation:
-
A locally advanced or metastatic solid tumor, where standard curative or palliative measures are no longer effective or are not considered appropriate or safe in the opinion of the investigator.
-
Measurable or non-measurable disease as determined by RECIST 1.1 or RANO as appropriate by tumor type.
-
Prior IDH1 inhibitor treatment is permitted.
Monotherapy Dose Expansion Cohort 1:
-
Histologically or cytologically confirmed diagnosis of advanced or metastatic cholangiocarcinoma, following 1 to 2 lines of prior systemic treatment for advanced disease. Prior IDH1 inhibitor treatment is not permitted.
-
Measurable disease as determined by RECIST 1.1.
Monotherapy Dose Expansion Cohort 2:
-
A locally advanced or metastatic solid tumor (except for cholangiocarcinoma), where standard curative or palliative measures are no longer effective or are not considered appropriate or safe in the opinion of the investigator.
-
Measurable disease as determined by RECIST 1.1 or RANO as appropriate by tumor types.
Monotherapy Dose Expansion Cohort 3:
-
A locally advanced or metastatic solid tumor, where standard curative or palliative measures are no longer effective or are not considered appropriate or safe in the opinion of the investigator.
-
Non-measurable disease only as determined by RECIST 1.1 or RANO as appropriate by tumor type.
Combination Dose Expansion Cohort 4:
-
Histologically or cytologically confirmed diagnosis of advanced or metastatic cholangiocarcinoma, not eligible for curative resection.
-
No prior systemic therapy for advanced or metastatic disease with the following exceptions:
- Patients who received adjuvant chemotherapy are eligible, if the adjuvant therapy was completed at least 6 months prior to the development of advanced or metastatic disease.
- Patients who are receiving up to two cycles of cisplatin plus gemcitabine as the first line systemic therapy while waiting for results of molecule profiling including IDH1/IDH2 mutational status, are eligible, provided that a radiographic assessment during screening demonstrates the absence of interval disease progression since initiation of chemotherapy treatment, and all other eligibility criteria are met.
-
Measurable disease as determined by RECIST 1.1.
Combination Dose Expansion Cohort 5:
-
Cholangiocarcinoma patients with IDH1 R132, IDH2 R140, or IDH2 R172 mutations
-
Histologically or cytologically confirmed diagnosis of advanced or metastatic cholangiocarcinoma, following 1 or more lines of prior systemic treatment for advanced disease.
-
Measurable disease as determined by RECIST 1.1
-
Had an investigational agent or anticancer therapy within 2 weeks; or investigational monoclonal antibody within 4 weeks prior to planned start of LY3410738.
-
Had major surgery within 4 weeks prior to planned start of LY3410738.
-
Had radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment, except for patients receiving whole brain radiotherapy, which must be completed at least 4 weeks prior to the first dose of study treatment.
-
Patients with cholangiocarcinoma: underwent hepatic radiation, chemoembolization and radiofrequency ablation, radioembolization or other locoregional therapy <4 weeks, have history of hepatic encephalopathy of any grade, have ascites requiring intervention such as diuretics or paracentesis, have ongoing cholangitis, have mixed hepatocellular biliary tract cancer histology or history of liver transplant.
-
Have active CNS metastases are not eligible. Patients with asymptomatic and treated brain metastases may participate provided that they are stable and are not requiring steroid treatment. Patients with suspected or confirmed leptomeningeal disease are not eligible even if treated.
-
Have primary CNS tumors are eligible provided that they do not have leptomeningeal disease and are on a stable or decreasing steroid dose for 7 days prior to screening. Patients with evidence of intracranial hemorrhage either by MRI or CT are not eligible
-
Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 at the time of starting study treatment except for alopecia.
-
Have clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of study treatment.
-
Have active uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the investigator and the sponsor makes it undesirable for the patient to participate in the trial. Screening for chronic conditions is not required.
-
Known active hepatitis B virus (HBV). Note: Controlled (treated) hepatitis will be allowed if they meet the following criteria, antiviral therapy for HBV must be given for at least 1 month prior to first dose of study drug, and HBV viral load must be less than 2000 IU/ml (104 copies/ml) prior to the first dose of study drug. Those on active HBV therapy with viral loads under 2000 IU/ml (104 copies/ml) should stay on the same therapy throughout the study treatment (Appendix E).
-
Known active hepatitis C virus (HCV). Note: Untreated patients with chronic infection by HCV are allowed on study. In addition, successfully treated patients with chronic infection by HCV (defined as sustained virologic response SVR12 or SVR24) are allowed, as long as a minimum of 4 weeks has elapsed between achieving sustained viral response (SVR12 or SVR24) and starting study drug.
-
Known human immunodeficiency virus (HIV); excluded due to potential drug-drug interactions between anti-retroviral medications and LY3410738.
-
Current treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers (Appendix F) and/or P-gp inhibitors (Appendix G).
-
Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug.
-
Active second malignancy unless in remission and with life expectancy > 2 years. Refer to protocol exclusion criteria (Section 4.2) for examples of allowed second malignancies.
-
Pregnancy, lactation or plans to breastfeed during the study or within 3 months of the last dose of study intervention.
-
Patients with known hypersensitivity to any component of LY3410738 or its formulation.
Combination Dose Expansion Cohort 5:
-
Prior treatment with anti-PD 1 or anti-PD L1 therapies.
-
History of Grade 3 or higher immune-related adverse events (irAEs).
-
Active autoimmune disease that has required systemic anti-autoimmune treatment in the past 2 years.
Endocrine replacement therapy is not considered a form of systemic therapy and is allowed.
-
Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids which should not exceed 10 mg/day of prednisone or equivalent corticosteroid.
-
Active interstitial lung disease or history of noninfectious pneumonitis Grade 2 or higher that required treatment with systemic corticosteroids or immunosuppressive drugs.
-
History of hypersensitivity to durvalumab or any excipient.
-
Has received a live vaccine within 30 days prior to the first dose of study drug.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description LY3410738 alone or in combination with gemcitabine and cisplatin or in combination with durvalumab LY3410738 Phase 1 dose expansion - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of LY3410738 alone or in combination with gemcitabine plus cisplatin or in combination with durvalumab LY3410738 LY3410738 Phase 1 dose escalation - Multiple doses of LY3410738 LY3410738 alone or in combination with gemcitabine and cisplatin or in combination with durvalumab Gemcitabine Phase 1 dose expansion - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of LY3410738 alone or in combination with gemcitabine plus cisplatin or in combination with durvalumab LY3410738 alone or in combination with gemcitabine and cisplatin or in combination with durvalumab Cisplatin Phase 1 dose expansion - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of LY3410738 alone or in combination with gemcitabine plus cisplatin or in combination with durvalumab LY3410738 alone or in combination with gemcitabine and cisplatin or in combination with durvalumab Durvalumab Phase 1 dose expansion - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of LY3410738 alone or in combination with gemcitabine plus cisplatin or in combination with durvalumab
- Primary Outcome Measures
Name Time Method Recommended Phase 2 Dose (RP2D) Up to 24 months
- Secondary Outcome Measures
Name Time Method Objective Response Rate Up to 24 months Assess the safety and tolerability of LY3410738 when administered alone or in combination with cisplatin plus gemcitabine or in combination with durvalumab Up to 24 months To assess the preliminary anti-tumor activity of LY3410738 when administered alone or in combination with cisplatin plus gemcitabine or in combination with durvalumab Up to 24 months Characterize PK properties of LY3410738 when administered alone or in combination with cisplatin plus gemcitabine or in combination with durvalumab Up to 24 months To characterize the pharmacodynamic properties of LY3410738 as expressed by change in 2-HG oncometabolite levels in plasma Up to 24 months
Trial Locations
- Locations (30)
USC Norris Cancer Hospital
🇺🇸Los Angeles, California, United States
University of Chicago Pritzker School of Medicine
🇺🇸Chicago, Illinois, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Indiana University School of Medicine
🇺🇸Indianapolis, Indiana, United States
University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Sarah Cannon Cancer Center
🇺🇸Nashville, Tennessee, United States
South Texas Accelerated Research Therapeutics, LLC
🇺🇸San Antonio, Texas, United States
The John Hopkins Hospital
🇺🇸Baltimore, Maryland, United States
Prince of Wales Hospital
ðŸ‡ðŸ‡°Hong Kong, Shatin, New Territories, Hong Kong
National Cancer Center Hospital East
🇯🇵Kashiwa, Chiba, Japan
Shizuoka Cancer Center
🇯🇵Nagaizumi, Shizuoka, Japan
National Cancer Center Hospital
🇯🇵Chuo-ku, Tokyo, Japan
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Mayo Clinic of Scottsdale
🇺🇸Phoenix, Arizona, United States
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
🇫🇷Bordeaux, France
Gustave Roussy
🇫🇷Villejuif Cedex, France
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Kanagawa Cancer Center
🇯🇵Yokohama, Kanagawa, Japan
The University of Arizona Cancer Center
🇺🇸Tucson, Arizona, United States
Osaka University Hospital
🇯🇵Suita-shi, Osaka, Japan
Mayo Clinic in Florida
🇺🇸Jacksonville, Florida, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
St Vincent's Hospital Sydney
🇦🇺Darlinghurst, New South Wales, Australia
National University Hospital
🇸🇬Singapore, Singapore
Samsung Medical Center
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
China Medical University Hospital
🇨🇳Taichung City, Taiwan
Hospital Universitario Vall d'Hebron
🇪🇸Barcelona, Spain
National Cheng-Kung Uni. Hosp.
🇨🇳Tainan, Taiwan
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain